The Use of Cilostazol in Patients With Diabetic Nephropathy
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
Patients with type 2 diabetes have a long duration of disease for the development of
complications. Among all complications, microangiopathic complications are major causes of
mortality and morbidity in diabetic patients. In Asia, patients with type 2 diabetes are
particularly susceptible to the development of kidney disease. Patients with diabetic kidney
disease have more adverse metabolic profiles and increased risk of having other complications
such as blindness, stroke, heart attack and nerve damage than those without. Despite
receiving the best of care, the combined event rate of death, cardiovascular disease and end
stage kidney disease in diabetic patients with renal impairment remained as high as 10% per
year.
Cilostazol reduces platelet aggregation and prevents formation of blood clots. Furthermore,
cilostazol treatment has been shown to reduce serum triglyceride concentrations and increase
HDL-cholesterol levels. In this randomized placebo-controlled, double-blinded study, the
investigators hypothesize that Cilostazol may reduce the rate of decline in renal function in
Chinese patients with type 2 diabetes and mild to moderate renal impairment. Sixty patients
will be randomised to receive either Cilostazol 100 mg twice daily or placebo for 12 months.
The effect of Cilostazol on the progression of diabetic nephropathy, as defined by rates of
decline in glomerular filtration rate, serum creatinine and urinary albumin excretion rate
will be measured. The results will provide additional insight on the management of diabetic
kidney disease which is prevalent among Chinese diabetic patients in Hong Kong.